home / stock / regmf / regmf news
2024-04-07 06:30:00 ET Summary ProfoundBio, a Seattle ADC company with an R&D facility in Suzhou, will be acquired by Copenhagen’s Genmab A/S in a $1.8 billion all-cash deal. China Medical System in-licensed povorcitinib, an oral JAK1 inhibitor, from San Franciscoȁ...
2024-03-17 03:20:00 ET Summary BIO, the global lobbying organization for biotechnology firms, forced WuXi AppTec to leave the group due to pressure from the US Congress. Germany’s Boehringer Ingelheim acquired an option to license drug candidates that treat all symptoms of ...
2023-10-01 03:30:00 ET Summary Adlai Nortye completes a $97.5 million IPO on NASDAQ, with its lead drug in a Phase III clinical trial for head and neck squamous cell carcinoma. Nanjing Triastek raises $20 million in a Pre-C financing round to support the development of its 3D prin...
2023-09-20 23:40:00 ET Summary RemeGen’s sales expenses reached around 83% of sales income in the first half of the year, and the company has flagged up a need for more spending. The pharma firm has applied to have the use of its autoimmune drug broadened to include arthrit...
2023-06-11 08:30:00 ET Summary Shenzhen HighTide Therapeutics filed for an IPO on the Hong Kong Exchange to develop a portfolio of novel multifunctional drugs for metabolic and digestive diseases. Shanghai Fosun Pharma will partner with World Bank affiliate International Finance C...
Summary Chia Tai-Tianqing Pharma, a subsidiary of Sino Biopharm, in-licensed Greater China rights to a therapy for non-alcoholic steatohepatitis from France’s Inventiva in a $307 million deal. Immuno Cure, a Hong Kong biotech focused on DNA vaccines and immunotherapies, acq...
RemeGen, a Yantai biotech with a deep portfolio of antibody and dual therapies, completed a $410 million IPO on the Shanghai Star Exchange. Nanjing Biosion out-licensed global rights (ex-China) to Pyxis Oncology for an immunotherapy aimed at solid tumor cancers in a $226 million agree...